Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M877Revenue $M1.1Net Margin (%)-3,128.4Z-Score46.3
Enterprise Value $M801EPS $-1.2Operating Margin %-3,118.6F-Score4
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-2,381.5Higher ROA y-yY
Price/Book13.510-y EBITDA Growth Rate %0Quick Ratio20.3Cash flow > EarningsY
Price/Sales8795-y EBITDA Growth Rate %0Current Ratio20.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-46.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-55.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M27.9ROI % (ttm)-59.8Gross Margin Increase y-yN

Gurus Latest Trades with NLNK

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NLNKJean-Marie Eveillard 2014-03-31 Add0.02%$21.38 - $50.4
($33.68)
$ 31.44-7%Add 28.35%1,161,805
NLNKJean-Marie Eveillard 2013-09-30 Add0.01%$15.78 - $20.08
($17.83)
$ 31.4476%Add 21.32%778,354
NLNKJean-Marie Eveillard 2013-06-30 Add0.02%$11.27 - $22.56
($15.73)
$ 31.44100%Add 95.04%641,554
NLNKJean-Marie Eveillard 2013-03-31 Buy 0.01%$11.4 - $12.7
($12.08)
$ 31.44160%New holding, 328939 sh.328,939
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NLNK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NLNK Jean-Marie Eveillard 2014-06-301,306,9704.680.08+12.49%
NLNK - CALLJean-Marie Eveillard 2014-06-307,1470.030.01
Premium Most recent portfolio changes are included for Premium Members only!


NLNK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ramsey William J.Quality Assurance Officer 2014-10-16Sell5,000$304.8view
Link Charles J. Jr.Chairman of the Board and CEO 2014-10-06Sell20,000$22.7238.38view
Ramsey William J.Quality Assurance Officer 2014-10-01Sell2,500$23.2535.23view
Link Charles J. Jr.Chairman of the Board and CEO 2014-09-05Sell20,000$25.6822.43view
Ramsey William J.Quality Assurance Officer 2014-09-02Sell2,500$26.419.09view
Link Charles J. Jr.Chairman of the Board and CEO 2014-08-05Sell18,000$21.8344.02view
Ramsey William J.Quality Assurance Officer 2014-08-01Sell2,500$20.4353.89view
Link Charles J. Jr.Chairman of the Board and CEO 2014-07-08Sell20,000$2620.92view
Ramsey William J.Quality Assurance Officer 2014-07-01Sell2,500$27.3315.04view
Ramsey William J.Quality Assurance Officer 2014-06-06Sell66$2057.2view

Press Releases about NLNK :

    Quarterly/Annual Reports about NLNK:

    News about NLNK:

    Articles On GuruFocus.com
    NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
    Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 


    More From Other Websites
    'Fast Money' Recap: How Much Higher Can Apple Shares Go? Oct 21 2014
    NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% Oct 21 2014
    After weeks of volatile trading, major averages move steadily higher Oct 20 2014
    EU offers benefits of "orphan" disease status to Ebola drugs Oct 20 2014
    Ebola outbreak: Cashing in on a cure Oct 20 2014
    Why NewLink Genetics (NLNK) Stock Is Soaring Today Oct 20 2014
    Stocks Open Quietly Mixed; Hasbro, NewLink, Akorn Rising Oct 20 2014
    NewLink Scores Major Partners With Roche’s Genentech Oct 20 2014
    NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO... Oct 20 2014
    NewLink in $1 bln deal with Roche to develop cancer drug Oct 20 2014
    NEWLINK GENETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Oct 20 2014
    7:02 am NewLink Genetics announces exclusive worldwide licensing agreement for development of... Oct 20 2014
    NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO... Oct 20 2014
    NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO... Oct 20 2014
    NewLink Genetics (NLNK) Shows Strength: Stock Up 23.7% Oct 14 2014
    Newlink shares jump on start of Ebola vaccine study Oct 13 2014
    Mali health workers get experimental GSK vaccine in Ebola trials Oct 10 2014
    Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear Oct 09 2014
    The Ebola drug playbook Oct 07 2014
    [video] The Ebola drug playbook Oct 07 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK